Medication info
Gavsmate Tablet 50/500 mg

Gavsmate Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Novartis Korea Ltd.
Appearance
Bright yellow oval film-coated tablets
Packaging
60 tablets (10 tablets/PTP packaging × 6)
Approval status
Active

MFDS item code 201206684 · Approved 2012.09.03 · Insurance code 653602300

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes mellitus, the dose of this medication should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Vildagliptin doses above 100mg per day are not recommended. This medication is generally administered with or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no previous experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: The initial dose is one tablet of this medication 50/500mg once daily; the dose may be gradually increased to one tablet of 50/1000mg twice daily. 2. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medication may start at their existing doses of vildagliptin and metformin. Studies have not been conducted to evaluate the safety and efficacy of switching from other oral antihyperglycemic agents to this medication. Any change in treatment for type 2 diabetes may affect glycemic control, so caution and appropriate monitoring are required. If a dose is missed, take it with the next meal unless it is not yet time for the missed dose; do not take twice the dose at once to make up for the missed dose. Patients with hepatic impairment This medication is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment.

Ingredients

Importer
Novartis Korea Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by using vildagliptin and metformin together. It supports patients who are also managing their diet and exercising, enabling them to more effectively manage blood glucose levels. Improved blood sugar control aids in diabetes management and plays an important role in preventing complications.

How to take

Adult dose

For the treatment of patients with type 2 diabetes mellitus, the dose of this medication should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Vildagliptin doses above 100mg per day are not recommended. This medication is generally administered with or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no previous experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: The initial dose is one tablet of this medication 50/500mg once daily; the dose may be gradually increased to one tablet of 50/1000mg twice daily. 2. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medication may start at their existing doses of vildagliptin and metformin. Studies have not been conducted to evaluate the safety and efficacy of switching from other oral antihyperglycemic agents to this medication. Any change in treatment for type 2 diabetes may affect glycemic control, so caution and appropriate monitoring are required. If a dose is missed, take it with the next meal unless it is not yet time for the missed dose; do not take twice the dose at once to make up for the missed dose. Patients with hepatic impairment This medication is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment.

Precautions

This medication can cause severe lactic acidosis or hypoglycemia, and should not be administered to patients at risk for these symptoms. It is especially contraindicated for patients with moderate to severe renal impairment, severe heart failure, or acute cardiac conditions and sepsis. Patients undergoing examinations using radiocontrast iodinated agents should discontinue use of this medication 48 hours prior to the exam and only resume after confirming normal renal function. This medication is not administered to patients with hypersensitivity to it, type 1 diabetes patients, or patients with diabetic ketoacidosis. Caution should be exercised when administering to patients with severe infections, trauma, pre- and post-surgery, malnutrition, liver dysfunction, pulmonary dysfunction, or excessive alcohol consumption. It is safest not to administer this medication to pregnant or breastfeeding women. Due to the risk of hypoglycemia, caution is advised in cases of irregular meals, intense exercise, or concurrent use of other blood sugar-lowering agents. During treatment, regular monitoring of liver and kidney function should be conducted, and any abnormalities should be reported to a physician immediately. If symptoms of acute pancreatitis occur, the medication should be stopped immediately and medical attention should be sought. Alcohol intake may increase the risk of side effects of this medication, so it is advisable to avoid drinking during treatment. Patients should be vigilant for symptoms of hypoglycemia and take appropriate action immediately if they occur. Elderly patients may have decreased renal function and require dose adjustment and regular monitoring of renal function. In the event of overdose, prompt medical attention should be sought, and hem dialysis may be necessary. Store this medication in a tightly closed container, out of reach of children, and do not transfer to another container. Particularly, this medication is not recommended for patients suspected of or diagnosed with mitochondrial diseases, and if any adverse symptoms occur, it should be discontinued immediately, and a diagnostic evaluation should be performed.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • hepatitis
  • liver dysfunction
  • increased transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
Show 44 more
  • nausea
  • hypoglycemia
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • blood glucose reduction
  • weakness
  • sweating
  • constipation
  • arthralgia
  • upper respiratory tract infection
  • rhinopharyngitis
  • peripheral edema
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • decreased appetite
  • taste disturbance
  • erythema
  • pruritus
  • urticaria
  • pancreatitis
  • blisters
  • exfoliative skin lesions
  • severe and disabling arthralgia
  • vasculitis
  • cholecystitis
  • dyspepsia
  • abdominal discomfort
  • gastrointestinal disturbances
  • increased serum amylase
  • increased lipase
  • blistering dermatitis herpetiformis
  • myalgia
  • paraesthesia
  • fever
  • edema
  • hand and foot swelling
  • elevated creatine phosphokinase
  • elevated AST
  • increased C-reactive protein
  • elevated myoglobin levels

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also advisable to keep it in a cool place with a temperature below 30 degrees.

Appearance and packaging

Appearance

Bright yellow oval film-coated tablets

Package unit

60 tablets (10 tablets/PTP packaging × 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.